28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.
18 May 2021Local decision makers should choose between the options for giving vancomycin orally. Licensing status and other factors affect decision making.
6 November 2020This updated Medicines Q&A is a quick reference summary to different types of enteral feeding tubes, in relation to medication issues. Not all enteral feeding…
4 November 2020Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to…
Medicine Compliance Aid Stability
VancocinFlynn Pharma Ltd
Flynn Pharma Ltd
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Powder is hygroscopic. Protect from light and store in airtight container. Maximum 7 days in MCA.
1 April 2015
Lactation Safety Information
Not absorbed from the infant's GI tract
Small amounts in breast milk
24 September 2020
AeroVancCystic fibrosis-associated MRSA lung infections - dry powder form in a capsule-based device
Development and Regulatory status
Dec 20Savara announce that PIII trial of AeroVanc in cystic fibrosis patients with methicillin-resistant Staphylococcus aureus (MRSA) lung infection failed to meet primary endpoints and development has been discontinued .
Dry powder inhalation formulation of vancomycin, a glycopeptide antibiotic.
Prevalence is 1 in 2,500 newborn, with calculated carrier frequency of 1 in 25. Over 9,000 people currently have CF in the UK.
Cystic fibrosis-associated MRSA lung infections - dry powder form in a capsule-based device